Department of Internal Medicine, Cardiology, Innsbruck Medical University, Austria.
Eur Heart J. 2011 Dec;32(23):2954-61. doi: 10.1093/eurheartj/ehr360. Epub 2011 Sep 14.
AIMS Pre-treatment with clopidogrel results in a reduction of ischaemic events in non-ST-elevation acute coronary syndromes. Data on upstream clopidogrel in the setting of primary percutaneous coronary intervention (PCI) are limited. The aim of this study was to investigate whether clopidogrel loading before arrival at the PCI centre may result in an improved outcome of primary PCI for ST-elevation myocardial infarction (STEMI). METHODS AND RESULTS In a multicentre registry of acute PCI, 5955 patients undergoing primary PCI in Austria between January 2005 and December 2009 were prospectively enrolled. The patients consisted of two groups, a clopidogrel pre-treatment group (n = 1635 patients) receiving clopidogrel before arrival at the PCI centre and a peri-interventional clopidogrel group (n = 4320 patients) receiving clopidogrel at a later stage. Multiple logistic regression analysis including major confounding factors stratified by the participating centres was applied to investigate the effect of pre-treatment with clopidogrel on the in-hospital mortality. Additionally, two subgroups, with or without the use of GP IIb/IIIa antagonist therapy in the catheterization laboratory, were analysed. On univariate analysis, clopidogrel pre-treatment was associated with a reduced in-hospital mortality (3.4 vs. 6.1%, P< 0.01) after primary PCI. On multivariate analysis, clopidogrel pre-treatment remained an independent predictor of in-hospital mortality [odds ratio (OR) = 0.60, 95% confidence interval (CI) 0.35-0.99; P =0.048], especially in patients receiving additional GP IIb/IIIa antagonist therapy in the catheterization laboratory (OR = 0.40, 95% CI 0.19-0.83; P =0.01). CONCLUSION Clopidogrel pre-treatment before arrival at the PCI centre is associated with reduced mortality in a real world setting of primary PCI. These results strongly support the recommendation of clopidogrel treatment 'as soon as possible' in patients with STEMI undergoing pimary PCI.
在非 ST 段抬高型急性冠状动脉综合征患者中,氯吡格雷预处理可降低缺血事件的发生。在直接经皮冠状动脉介入治疗(PCI)的情况下,有关氯吡格雷的上游数据有限。本研究旨在探讨在直接 PCI 中心就诊前给予氯吡格雷负荷剂量是否可以改善 ST 段抬高型心肌梗死(STEMI)患者的直接 PCI 结局。
在一项急性 PCI 的多中心注册研究中,前瞻性纳入了 2005 年 1 月至 2009 年 12 月期间在奥地利接受直接 PCI 的 5955 例患者。这些患者分为两组:氯吡格雷预处理组(n = 1635 例)在到达 PCI 中心前接受氯吡格雷治疗,介入围术期氯吡格雷组(n = 4320 例)在稍后阶段接受氯吡格雷治疗。应用多变量逻辑回归分析(包括按参与中心分层的主要混杂因素),以探讨直接 PCI 前使用氯吡格雷对住院死亡率的影响。此外,还分析了在导管室中使用或不使用 GP IIb/IIIa 拮抗剂治疗的两个亚组。单因素分析显示,直接 PCI 前应用氯吡格雷与住院死亡率降低相关(3.4% vs. 6.1%,P<0.01)。多变量分析显示,直接 PCI 前应用氯吡格雷仍然是住院死亡率的独立预测因素[比值比(OR)=0.60,95%置信区间(CI)0.35-0.99;P=0.048],特别是在导管室中接受额外 GP IIb/IIIa 拮抗剂治疗的患者中(OR=0.40,95%CI 0.19-0.83;P=0.01)。
在直接 PCI 的真实世界环境中,直接 PCI 中心就诊前应用氯吡格雷与死亡率降低相关。这些结果有力支持了对 STEMI 患者行直接 PCI 时氯吡格雷治疗“尽快”的推荐。